In glioma patients, TGF-β suppress immune responses by several mechanisms, including the blockade of the major histocompatibility complex (MHC) class II expression in glioma cells [65,66,67,68,69] and deactivation of natural killer (NK) cells [70] and cytotoxic T cells [71]. Here, HLA-C is linked to central nervous system cancer.